Dr. Elhassadi on 10-Year Single-Center Experience With TP53 Status in MCL

Video

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).

At the 2019, ASCO Annual Meeting, Elhassadi presented the 10-year single-center experience data with TP53 status in patients with MCL. Twenty-nine previously treated patients were recruited to the study where investigators collected 32 patient samples. Patients received a variety of combinations. Over the study period, which ranged from 2006 to 2016, 11 deaths were reported. Of the 11 deaths, 6 were non-lymphoma—related and 5 were lymphoma-related as a result of disease progression.

These data fell in line with published literature in the field, says Elhassadi. Further analysis from p53 mutation screening in the lymphoma-related cohort revealed that as many as 80% of patients harbored a p53 mutation, which is a known poor prognostic indicator in MCL.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS